VERTISIN Cinnarizine 25mg Tablet 1's
RXDRUG-DR-XY25924-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Symptomatic treatment of nausea and vertigo caused by Meniere's disease and other labyrinth disorders and for the prevention and treatment of motion sickness. Management of various peripheral and cerebral vascular disorders.
Dosage/Direction for Use
1-3 tablets 3 times a day.
Administration
Should be taken with food.
Contraindications
Pregnancy & women of childbearing potential.
Special Precautions
General: In patients suspected of intracranial hemorrhage, administration of Vertisin should be initiated from 10 days to 2 weeks after the attack where hemostasis has been estimated to be established.
Use in pregnancy: In animal studies (rats and mice), the incidence of cleft palate has been reported. Use of cinnarizine should be avoided in pregnant women or women of childbearing potential.
Use in pregnancy: In animal studies (rats and mice), the incidence of cleft palate has been reported. Use of cinnarizine should be avoided in pregnant women or women of childbearing potential.
Use In Pregnancy & Lactation
Use in pregnancy: In animal studies (rats and mice), the incidence of cleft palate has been reported. Use of cinnarizine should be avoided in pregnant women or women of childbearing potential.
Adverse Reactions
Gastrointestinal: Occasionally, symptoms including nausea, anorexia and diarrhea have occurred.
Nervous System: Occasionally, symptoms including headache, dizziness, somnolence and fatigue have occurred.
Hypersensitivity: Occasionally, hypersensitivity symptoms including eruption and erythema on the skin or mucous membrane have occurred. When these symptoms have occurred, Vertisin should be discontinued immediately.
Nervous System: Occasionally, symptoms including headache, dizziness, somnolence and fatigue have occurred.
Hypersensitivity: Occasionally, hypersensitivity symptoms including eruption and erythema on the skin or mucous membrane have occurred. When these symptoms have occurred, Vertisin should be discontinued immediately.
Storage
Store at a temperature not exceeding 30°C.
Action
Antivertigo.
Cinnarizine is a selective calcium-entry blocker, belonging to group IV of calcium antagonists. It inhibits contractions of vascular smooth muscle cells by blocking calcium channels. In addition, it decreases the contractile activity of vasoactive substances eg, norepinephrine and serotonin, resulting to a remarkable improvement of cerebral blood flow.
Cinnarizine further improves deficient microcirculation by increasing erythrocyte deformity and decreasing blood viscosity. Cellular resistance to hypoxia is increased. Cinnarizine inhibits stimulation of the vestibular system, which results in suppression of nystagmus and other autonomic disturbances. Acute episodes of vertigo can be prevented or reduced.
Cinnarizine is a selective calcium-entry blocker, belonging to group IV of calcium antagonists. It inhibits contractions of vascular smooth muscle cells by blocking calcium channels. In addition, it decreases the contractile activity of vasoactive substances eg, norepinephrine and serotonin, resulting to a remarkable improvement of cerebral blood flow.
Cinnarizine further improves deficient microcirculation by increasing erythrocyte deformity and decreasing blood viscosity. Cellular resistance to hypoxia is increased. Cinnarizine inhibits stimulation of the vestibular system, which results in suppression of nystagmus and other autonomic disturbances. Acute episodes of vertigo can be prevented or reduced.
MedsGo Class
Antivertigo Drugs / Peripheral Vasodilators & Cerebral Activators
Features
Brand
VERTISIN
Full Details
Dosage Strength
25 mg
Drug Ingredients
- Cinnarizine
Drug Packaging
Tablet 1's
Generic Name
Cinnarizine
Dosage Form
Tablet
Registration Number
DR-XY25924
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply